Helix BioPharma Corp. (HBP : TSX)
Common Stock
$1.48
CAD
-0.02 (-1.33%)
Last updated: 2026-08-04
Get HBP alerts:
HBP
Helix BioPharma Corp.
WealthAwesomePerformance
1 Day
-1.33%
1 Week
+2.07%
1 Month
+5.71%
YTD
-38.33%
Key Statistics
Market Cap
$114.57M
52W High
$5.40
52W Low
$0.98
P/E Ratio
-
50 Day MA
$1.48
200 Day MA
$1.91
Beta
-0.35
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 8/4/2026 | $1.48 | $1.48 | $1.48 | $1.48 | $1.48 | 416 |
| 7/31/2026 | $1.50 | $1.50 | $1.50 | $1.50 | $1.50 | 0 |
| 7/30/2026 | $1.44 | $1.50 | $1.44 | $1.50 | $1.50 | 1,400 |
| 7/29/2026 | $1.45 | $1.50 | $1.44 | $1.50 | $1.50 | 450 |
| 7/28/2026 | $1.45 | $1.45 | $1.44 | $1.45 | $1.45 | 1,102 |
| 7/27/2026 | $1.41 | $1.44 | $1.41 | $1.44 | $1.44 | 306 |
| 7/24/2026 | $1.42 | $1.42 | $1.42 | $1.42 | $1.42 | 218 |
| 7/23/2026 | $1.44 | $1.44 | $1.41 | $1.44 | $1.44 | 1,100 |
| 7/22/2026 | $1.43 | $1.43 | $1.40 | $1.40 | $1.40 | 200 |
| 7/21/2026 | $1.10 | $1.44 | $1.10 | $1.40 | $1.40 | 2,340 |
Analyst Price Targets
Based on analyst covering HBP
Wall Street analysts forecast HBP stock price to rise 68.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+68.9% Upside
Current Price
C$1.48
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
48.7%
Annualized
90-Day Vol
65.6%
Annualized
Trend (90d)
-43.1%
Annualized drift
90d Mean
C$1.27
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.41 | C$1.19 – C$1.66 |
| 60 trading days | C$1.34 | C$1.05 – C$1.69 |
| 90 trading days | C$1.27 | C$0.95 – C$1.70 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Helix BioPharma Corp.
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer; and LDOS007, which is in phase Ib/II for the treatment of lung cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company has an agreement with metaShape Pharma AG for covering LEUMUNA, within the field of adipose tissue-related and metabolic diseases. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-3.25M
- Profit Margin
- 0.00%
- ROE (TTM)
- -49.99%
- EPS (Diluted)
- -0.04
- Book Value
- 0.19
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
🔄 Recent Splits
1-for-5
Aug 16, 2024
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About HBP
Market movers
Recent TSX movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| TSAT | Telesat Corp | $76.84 | +47.57% |
| INC-UN | Income Financial Trust | $10.30 | +24.85% |
| TINY | Tiny Ltd. | $7.50 | +24.38% |
| TLO | Talon Metals Corp | $6.04 | +20.08% |
| IE | Ivanhoe Energy Inc | $14.98 | +19.84% |
| SXGC | Southern Cross Gold Consolidated Ltd. | $10.69 | +18.78% |
| AYA | Aya Gold & Silver Inc | $32.18 | +16.85% |
| TKO | Taseko Mines Ltd | $11.01 | +16.38% |
HBP.TO news timeline
15 articles covering HBP.TO, most recent first
LatestWhy Helix BioPharma Corp. stock is sliding today
July 2026
- What's Going On With Helix BioPharma Corp. Stock Friday?
- Why Helix BioPharma Corp. stock is rising today
- Why Helix BioPharma Corp. stock is sliding today
- What's Going On With Helix BioPharma Corp. Stock Tuesday?
- Why Helix BioPharma Corp. stock is sliding today
- Why Helix BioPharma Corp. stock is plummeting today
- Why Helix BioPharma Corp. stock is plummeting today
- Why Helix BioPharma Corp. stock is sliding today
- What's Going On With Helix BioPharma Corp. Stock Wednesday?
- Why Helix BioPharma Corp. stock is sliding today
- Why Helix BioPharma Corp. stock is rising today
- Why Helix BioPharma Corp. stock is sliding today
- Why Helix BioPharma Corp. stock is sliding today
- Why Helix BioPharma Corp. stock is rising today